WW International Q2 revenue beats estimates on Clinical growth

WW International reaffirmed full-year 2026 revenue guidance of $620 million to $635 million.

The company also maintained 2026 adjusted EBITDA guidance of $105 million to $115 million and said it sees continued momentum in Core+ and Clinical subscriber growth.

• Clinical Subscription Revenue rose 30.4% year over year, and Clinical subscribers increased 55.7%, despite lapping significant prior-year growth.
• The Core+ Behavioral tier posted its third consecutive quarter of sequential subscriber growth, up 13.9% year over year.
• Monthly subscription revenue per average subscriber increased 10.2% year over year, driven by a shift toward Clinical offerings.